NEWS

抄読会論文
  • Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study

    2024.07.10 | 抄読会論文
    抄読会要旨 今村光佑...
  • eClinical Medicine. 2024 Mar 22:70:102536. doi:10.1016/j.eclinm.2024.102536Title : Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective

    2024.06.7 | 抄読会論文
    抄読会要旨 猪山慎治...
  • First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462.

    2024.05.16 | 抄読会論文
    抄読会要旨 猿渡 功一...
  • Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy

    2024.02.19 | 抄読会論文
    抄読会要旨 岡林比呂子...
  • Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer

    2023.11.1 | 抄読会論文
    抄読会要旨 今村光佑...
  • Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

    2023.10.27 | 抄読会論文
    抄読会要旨 猪山慎治...
  • High yield of pleural cell-free DNA for diagnosis of oncogenic mutations in lung adenocarcinoma

    2023.10.12 | 抄読会論文
    抄読会要旨 木村俊貴...
  • Efzofitimod for the Treatment of Pulmonary Sarcoidosis

    2023.09.21 | 抄読会論文
    抄読会要旨 岡林比呂子...
  • Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer N Engl J Med. 2023 Jun 3. doi: 10.1056/NEJMoa2302983. Online ahead of print.

    2023.07.4 | 抄読会論文
    抄読会要旨 猿渡功一...
  • Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

    2023.05.8 | 抄読会論文
    抄読会要旨 御任玲美...
Copyright© 2024 熊本大学大学院生命科学研究部 呼吸器内科学分野 All rights reserved.